World shares steady, dollar firms on US tariff letters
Shares on Wall Street fell after Trump sent letters to 14 countries, including Japan and South Korea, unveiling sharply higher tariffs on imports into the United States, while also postponing their implementation to August 1.
Japan's Nikkei stock gauge opened lower on Tuesday but then turned positive after Trump described that deadline as "firm, but not 100 per cent firm" and said tariffs may be adjusted for some countries.
The Australian dollar rose ahead of a Reserve Bank of Australia decision later in the day.
Market reaction to the tariff announcements was muted on memories of Trump's rapid walk-back of his "Liberation Day" duties initially set out on April 2, said Tapas Strickland, head of market economics at National Australia Bank.
"There's going to be a lot of volatility as the headlines start to emerge, as more of these letters come out, and as the negotiations really come to the fore ahead of that August 1 deadline," Strickland said on an NAB podcast.
In April, Trump capped all of the so-called reciprocal tariffs with trading partners at 10 per cent until July 9 to allow for negotiations. Only two agreements, with Britain and Vietnam, have been reached.
In June, Washington and Beijing agreed on a framework covering tariff rates, restoring a fragile truce in their trade war. Tariffs on Japan and South Korea are now due to go up to 25 per cent on August 1.
Japanese Prime Minister Shigeru Ishiba called the hike deeply regrettable and said his nation would continue negotiations with the US.
The European Union will not be receiving a letter setting out higher tariffs, EU sources familiar with the matter told Reuters on Monday. The EU still aims to reach a trade deal by Wednesday after European Commission President Ursula von der Leyen and Trump had a "good exchange", a commission spokesperson said.
MSCI's broadest index of Asia-Pacific shares outside Japan was up 0.2 per cent in early trade. Japan's Nikkei stock index rose 0.4 per cent while South Korea's KOSPI jumped 1.5 per cent.
The dollar rose 0.2 per cent to 146.36 yen, touching a two-week high. The euro was flat at $US1.1741. The Aussie advanced 0.4 per cent to $US0.6516 before a meeting by the central bank where policymakers are widely expected to deliver a 25-basis-point cut.
US crude dipped 0.5 per cent to $US67.59 a barrel after surging nearly two per cent on Monday. Spot gold edged 0.2 per cent lower. In early trade, pan-region Euro Stoxx 50 futures were down 0.1 per cent, German DAX futures were down 0.1 per cent at 24,133, and FTSE futures slid 0.3 per cent.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
18 minutes ago
- Sky News AU
Former CIA and FBI directors now under criminal investigation
Former CIA director John Brennan and former FBI director James Comey are under criminal investigation for their handling of the Trump-Russia probe. A Justice Department source revealed to Fox News that the pair are also being investigated for allegedly making false statements to Congress. FBI Director Kash Patel was referred to evidence of potential wrongdoing by Brennan from the current CIA Director John Ratcliffe, a DOJ source said. According to Fox News, a source revealed that an investigation into Brennan is underway, but further details were not given. It is currently unclear whether the investigation into the former CIA head goes beyond his alleged false statements to Congress. An investigation into the former FBI director Comey is underway, though sources could not divulge further information.
Sky News AU
18 minutes ago
- Sky News AU
Australian dollar sees sharp move following shock RBA cash rate decision
InTouch Capital Markets' Sean Callow claims he was 'surprised' by the RBA's cash rate decision. This comes amid the Reserve Bank of Australia deciding to keep the cash rate on hold at 3.85 per cent despite wide speculation of a rate cut. 'I was surprised, and the Aussie dollar reaction tells you that FX traders were as well,' Mr Callow told Sky News Business Reporter Edward Boyd.
News.com.au
21 minutes ago
- News.com.au
‘Screw over': Truth about Donald Trump's plan to impose crippling 200 per cent tariffs on Australian pharmaceuticals
US President Donald Trump's plan to drop a 200 per cent tariff bomb on Australian pharmaceuticals is set to 'screw over' the sickest and most vulnerable in the United States suffering rare and life-threatening conditions including burns patients. As the Albanese Government scrambles to secure more information about the US government's latest plans, Australian officials are sounding the alarm given that pharmaceutical exports are worth over $2 billion a year. All plasma products collected in Australia stay here and are not exported to the US. Instead, the export issue relates to vaccines and blood products collected overseas and sent to Australia for processing before being returned to the US. President Donald Trump has threatened to introduce 200 per cent tariffs on pharmaceuticals – one of Australia's biggest exports to the US. Speaking to the media before a cabinet meeting, the President suggested the 'very, very high' levies on pharmaceuticals would not go into effect immediately, saying he would give drug manufacturers 'about a year, year and a half' to respond and relocate their operations to the US. 'They're going to be tariffs at a very high rate, like 200 per cent,' Mr Trump told reporters. 'We'll give them a certain period of time to get their act together,' he added, seemingly referring to drug manufacturers bringing back manufacturing into the US. Australia is subject to a 10 per cent 'baseline' tariff, which was the minimum rate imposed on all US trading partners by Mr Trump earlier this year. Australia's plasma exports to the US One of the biggest sections of the market includes blood products such as plasma products including exports linked to CSL Plasma which collects blood plasma in the United States. In 2023, Australia exported $1.42 billion of vaccines, blood, antisera, toxins and cultures, making it the 20th largest exporter of 208 in the world. Blood collection is a commercial operation in the United States, with plasma donors typically paid for their blood. CSL Plasma operates one of the world's largest and most sophisticated plasma collection networks, with nearly 350 plasma collection centers in the US and elsewhere. The blood products are mostly processed in the US but some are sent back to Australia to manufacture therapies for a variety of rare and life-threatening conditions. These conditions include primary immunodeficiencies, bleeding disorders like hemophilia, neurological disorders, and critical care needs like those arising from trauma or burns. One Australian official predicted that demand for the products would continue but the tariffs would 'screw over' patients relying on the notorious US healthcare system. Vulnerable patients will be hit with cost increases because the tariffs are paid by importers, not Australian exporters. CSL has a factory in Melbourne Biotech giant CSL has a plasma fractionation facility in Broadmeadows in Melbourne. The impact of the threatened tariffs relates to the commercial arm of CSL. which uses US blood products which are sourced in America and then processed in Australia before being sent back. 'Plasma manufacturing is a really fragile supply chain because it starts in a human vein,'' an industry source said. 'It's not a tap that you can turn on or off. You need people to vote with their feet to go into a facility that is enabled to collect plasma, and the demand for plasma products is growing globally each year.' 'Tariffs on pharmaceuticals impact the end user.' Treasurer Jim Chalmers 'very concerned' The Treasurer said on Wednesday that Washington's latest announcement was 'very concerning'. 'These are obviously very concerning developments,' Mr Chalmers told the ABC, adding that it had 'been a feature of recent months that we've had these sorts of announcements out of DC'. 'It's still early days. Obviously, we'll make a more detailed assessment of what's come out of the US in the usual way.' 'Our pharmaceuticals industry is much more exposed to the US market, and that's why we're seeking - urgently seeking - some more detail on what's been announced. 'But I want to make it really clear once again … our Pharmaceutical Benefit Scheme is not something that we're willing to trade away or do deals on – that won't change.' 'We've made it very clear that we think these tariffs are bad for the US, bad for Australia and bad for the global economy.' Mr Chalmers said one of the things the Albanese Government was 'most concerned' about was in addition to the direct impact on Australian workers and industries caused by this tariff, was the 'impact on global demand more broadly'. 'That's why we've been … at every opportunity, making the case that these tariffs are unjustified, they should be removed in line with our free trade agreement,' he said. The Prime Minister has described the taxes on Australian exports to the US as an 'act of economic self-harm'. 'Tariffs are a penalty on the country that is imposing them, because what they require is for goods to be purchased with a tax on top, and the US has made that decision,' the Prime Minister said. How plasma exports are used to help patients CSL Behring uses a process called plasma fractionation to separate the collected plasma into different components, such as immunoglobulins, coagulation factors, and other proteins. One example is helping people with bleeding disorders, with doctors utilising coagulation factors that are used to help patients with hemophilia and other bleeding disorders. Plasma-derived products are also used in emergency situations like severe trauma, burns, and shock to replace lost blood volume and proteins. For now, Australian officials concerned about the impact on blood product exports don't have full clarity on how it will impact the supply chain process.
